

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Islam Khalid</u> <hr/> (Last) (First) (Middle) 68 TW ALEXANDER DRIVE PO BOX 13628 <hr/> (Street) DURHAM NC 27709 <hr/> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 09/11/2017	3. Issuer Name and Ticker or Trading Symbol <u>FENNEC PHARMACEUTICALS INC. [FENC]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year) <hr/> 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
---------------------------------	---	--	---

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date				
Stock Option (right to buy)	04/25/2014	04/25/2021	Common shares	133,333	2.31	D
Stock Option (right to buy)	12/31/2014	12/31/2021	Common shares	10,000	2.69	D
Stock Option (right to buy)	12/11/2015	12/11/2022	Common shares	50,000	1.13	D
Stock Option (right to buy)	06/09/2016	06/09/2023	Common shares	20,492	2.44	D
Stock Option (right to buy)	06/27/2017	06/27/2024	Common shares	25,000	5.1	D

Explanation of Responses:

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney

/s/ Mark Gowland 09/21/2017

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

KNOW ALL MEN BY THESE PRESENTS:

Khalid Islam, Director & Chairman of the Board, Fennec Pharmaceuticals, Inc.
(if individual is signing for a company please state the position. ie, CEO.)

Here in after referred to as PRINCIPAL, in the

County of Harris

State of Texas

Do {es) appoint:

Mark Gowland, Controller
his {her) true and lawful attorney.

In principal's name, and for principal 's use and benefit, said attorney is authorized hereby:

(1) To execute, acknowledge, and deliver such written documentation with respect to completing and filing a **UNIFORM APPLICATION FOR ACCESS CODES TO FILE ON EDGAR with the U.S. Security and Exchange Commission**, all upon such terms and conditions as said attorney shall approve.

Giving and granting to said attorney full power and authority to do all and every act and thing whatsoever requisite and necessary to be done relative to any of the foregoing as fully to all intents and purposes as principal might or could do if personally present.

All that said attorney shall lawfully do or cause to be done under the authority of this power of attorney is expressly approved.

12 September 2017
Date

/s/ Khalid Islam
Signature
